Hope For HIV: Merck’s Drug For HIV Shows Promising Results
With continuous efforts of eradicating HIV, authorities from pharmaceutical giant Merck & Co Inc. (MRK) have recently announced the positive results obtained from its Phase 3 clinical trial evaluating the safety and efficacy of its HIV drug, doravirine (MK-1439). Since the company had started its quest for HIV, Merck has been considered to have taken a huge gap toward getting its lead HIV candidate doravirine from reaching the market, setting up a showdown with Johnson & Johnson's big-selling Prezista. Merck researchers said that doravirine has shown its value in a first phase 3 trial, matching the efficacy of a ritonavir-boosted Prezista regimen which is also referred to as darunavir in a span of over 48 weeks in previously untreated adults with HIV when given on top of standard two-drug antiretroviral regimens.
Doravirine: The Hope For HIV
According to reports revealed by Investopedia, the trial has allegedly compared the efficacy of two drug combinations, one that's consisting of doravirine with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), and another which is comprised of ritonavir-boosted darunavir with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), with the hopes of treating adults with previously untreated or considered as treatment-naïve from HIV-1 infection. Researchers have added that doravirine was also less likely to cause elevations in blood low-density lipoprotein cholesterol (LDL-c) levels, which has been well-known as a marker for the metabolic side effects linked to some antiretroviral drugs. Consequently, the study findings has been considered by the experts as a favorable result for doravirine, particularly as HIV protease inhibitor
Furthermore, in one of his statements reported by Fierce Biotech, during Merck's R&D head Roger Perlmutter said that doravirine has properties very much like efavirenz, which is another type of antiretroviral medication used to treat and prevent HIV/AIDS. However, experts have highly emphasized that Merck's doravirine consists of a substantially better safety profile which could lead it to be one of the dominant agents used in HIV treatment. It was also found that although HIV can generally be managed with available antiretroviral drugs, experts have claimed that there is still a need for new agents that overcome the limitations of earlier drugs, such as improved potency, dosing and tolerability, as well as effectiveness against drug-resistant strains of the virus.
Study Proposition For HIV
Meanwhile, director of infectious diseases at Thomas Jefferson University in Philadelphia, Dr. Kathleen Squires, has further revealed that the results of this study provide solid evidence of the efficacy and safety profile of doravirine as a potential treatment option for treatment-naive HIV-1 patients. Ultimately, experts have anticipated that there are currently around 37 million people worldwide living with HIV, with new infections occurring at a rate of about 2 million a year.
HIV, The Next Target Of Trump Administration
As continuous efforts to eradicate HIV are taking place, why does the Trump administration wanted to halt the treatment that has been started by the previous government? What’s the truth behind claims that if the current US President would push this through, it will kill thousands? Find out what authorities have to say
How Do We Reduce HIV Risk? Here Are Experts' Tips
With the continuous efforts to eradicate one of the world's long dreaded disease, can we really do certain precautionary measures to prevent the risk of HIV? What are the necessary steps to prevent transmission of the disease? Find out what experts have to say
HIV Vaccine Cures Five Patients For Seven Months
New AIDS vaccine developed in Spain have reportedly cured 5 patients, helping them remain virus-free for seven months after taking the treatment. In the study, the treatment allowed the patients to stop taking regular antiretroviral (ARV) drugs to suppress HIV symptoms.
Nanotechnology For HIV: New Technique Shows Promising Results In HIV Treatment
With continuous efforts to eradicate HIV being one of the world's long dreaded disease, how essential does nanotechnology's role can be? What's the truth behind claims that this new technique offers a new hope as it has induced positive results in HIV treatment? Could it be the answer to the disease? Find out what experts have to say
PrEP For HIV: Raising Awareness; Could It Be The Cure For The Disease?
Considering that HIV has been and is still currently is one of the world’s most dreaded diseases, how essential is the use of PrEP? Could it possibly hold the key for cure that a lot of people have been waiting for? What’s the truth behind claims these claims? Find out what health professionals have to say
HIV Update: The 'HIV Conserv’ Vaccine And Its Promising Results
Considering the continuous efforts to eradicate the global health problem brought by HIV, what's the truth behind claims of a researcher about the so-called 'kick and kill' strategy by being a potential key for the long dreaded disease? How effective is this trial and what are the chances of being cured from the disease? Find out what experts have to say
MORE IN ITECHPOST
iOS 11 Plagued with Untested Bugs and Early Adoption Pitfalls
Reports of nagging iOS 11 issues have started pouring in just a day after the software was released by Apple on supported devices.
'Tokyo Ghoul' Season 3 Delayed By Its Live-Action Movie? Ken Kenaki Returns With Another Identity?
"Tokyo Ghoul" season 3's release is delayed and there are countless speculations as to why it is being pushed back. Reports claim that the show is to give way to "One Punch Man" and "My Hero Acdemia" but new rumors say that it's lack of materials and storyline as well as its live-action movie are causing the delay.
‘Resident Evil 7: Not A Hero DLC’ First Gameplay Trailer Leaks Online
First gameplay trailer pertaining to RE7: Not A Hero DLC has just leaked on YouTube.